Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 6/20 | 0.63 |
| ▸ | TACR1 | P25103 | 3/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.56 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.56 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668648 | 0.88 | TACR1 (0.67) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL19686204 | 0.82 | SCN4A (0.54) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| Phosphoric Acid SCHEMBL11418491 | 0.80 | KDM4E (0.50) | TACR1L3MBTL1KDM4EMAOBAOC3 | |
| SCHEMBL9988187 | 0.80 | HTR2A (0.57) | SCN4ACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4345367 | 0.79 | SCN4A (1.00) | SCN4ATACR1 | |
| SCHEMBL12847267 | 0.79 | SCN4A (1.00) | SCN4ATACR1 | |
| SCHEMBL28303221 | 0.78 | L3MBTL1 (0.51) | L3MBTL1KDM4EMAOBAOC3 | |
| SCHEMBL16168405 | 0.78 | KDM4E (0.49) | L3MBTL1KDM4EMAOBAOC3 | |
| SCHEMBL19686722 | 0.77 | SCN4A (0.55) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL19668462 | 0.77 | TACR1 (0.53) | SCN4ATACR1CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492325-B2 | Compounds as inhibitors of sodium channels | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2022-11-08 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3494105-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | Human Biomolecular Research Institute (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885TACR1 174/4885CACNA1F 18/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | SCN4A 3286/4885TACR1 814/4885CACNA1F 4631/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | SCN4A 3286/4885TACR1 814/4885CACNA1F 4631/4885 |
| US-11492325-B2 | Compounds as inhibitors of sodium channels | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885TACR1 174/4885CACNA1F 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.